Cardinal Health upgraded to Buy from Hold at Jefferies

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks Cardinal’s earnings track record is “undeniable and clearly differentiated” versus its prior history under the new management. The company has laid the foundation to continue strong growth trends by adding strategic assets which should boost its exposure to the specialty pharma growth opportunity, the analyst tells investors in a research note. Jefferies believes the stock’s multiple expansion will continue as “growth expectations are validated.”